The place of targeted therapies in the management of non-small cell bronchial carcinoma: Molecular markers as predictors of tumor response and survival in lung cancer

Revue des Maladies Respiratoires

Volumn 23, Issue 5 C3, 2006, Pages

  Rosell, R ^a   Moran, T ^a   Fernanda Salazar, M ^a   Mendez, P ^a   De Aguirre, I ^a   Ramirez, J L ^a   Isla, D ^b   Cobo, M ^c   Camps, C ^d   Lopez Vivanco, G ^e   Alberola, V ^f   Taron, M ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^c HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^d HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^e HOSPITAL DE CRUCES   (Spain)

^f HOSPITAL ARNAU DE VILANOVA   (Spain)

Author keywords

Acquired resistance to tyrosine kinase inhibitors; BRCA1 mRNA; EGFR tyrosine kinase mutations; Estrogen receptors

Indexed keywords

BLEOMYCIN; BRCA1 PROTEIN; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ESTROGEN RECEPTOR; ETOPOSIDE; GEFITINIB; GEMCITABINE; MESSENGER RNA; NAVELBINE; PACLITAXEL; PROGESTERONE RECEPTOR; BIOLOGICAL MARKER;

CANCER SURVIVAL; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG SENSITIVITY; GENE MUTATION; GENE NUMBER; HUMAN; LUNG CANCER; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; REVIEW; GENETICS; LUNG CARCINOMA; LUNG TUMOR; MORTALITY; MUTATION; PROGNOSIS; SURVIVAL RATE;

BIOLOGICAL MARKERS; CARCINOMA, BRONCHOGENIC; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; MUTATION; PROGNOSIS; SURVIVAL RATE;

EID: 33751577524     PISSN: 07618425     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. Hoang T, Xu Ronghui, Schiller J H, Bonomi P, Johnson DH : Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on Eastern Cooperative Oncology Group data. J Clin Oncol 2005 ; 23 : 175-83.
2. Dabholkar M, Vionnet J, Bostick-Bruton F, Yu JJ, Reed E : Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest 1994 ; 94 : 703-8.
3. Lord RVN, Brabender J, Gandara D, Alberola V, Camps C, Domine M, Cardenal F, Sanchez JM, Gumerlock PH, Taron M, Sanchez JJ, Danenberg KD, Danenberg PV, Rosell R : Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small-cell lung cancer. Clin Cancer Res 2002 ; 8 : 2286-91.
4. Cobo M, Isla D, Sanchez JM, Massuti B, Montes A, Paz-Ares L, Muñoz MA, Viñolas N, Lopez-Vivanco G, Felip E, on behalf of the Spanish Lung Cancer Group : ERCC1 mRNA-based randomized phase III trial of docetaxel doublets with cisplatin or gemcitabine in stage IV non-small-cell lung cancer patients. Lung Cancer 2005 ; 49 : S32 (abstr O-089).
5. Husain A, He G, Venkatraman ES, Spriggs DR : BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum (II). Cancer Res 1998 ; 58 : 1120-3.
6. Quinn JE, Kennedy RD, Mullan PB, Gilmore PM, Carty M, Johnston PG, Harkin DP : BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res 2003 ; 63 : 6221-8.
7. Turner N, Tutt A and Ashworth A : Hallmarks of "BRCAness" in sporadic cancers. Nat Rev Cancer 2004 ; 4 : 1-6.
8. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, Martin NM, Jackson SP, Smith GC, Ashworth A : Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005 ; 434 : 917-21.
9. Taron M, Rosell R, Felip E, Mendez P, Souglakos J, Sanchez-Ronco M, Queralt C, Majo J, Sanchez JM, Sanchez JJ, Maestre J : BRCA mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum Mol Genet 2004 ; 13 : 2443-9.
10. Rosell R, Danenberg KD, Alberola V, Bepler G, Sanchez JJ, Camps C, Provencio M, Isla D, Taron M, Diz P, Artal A : Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small-cell lung cancer patients. Clin Cancer Res 2004 ; 10 : 1318-25.
11. Achiwa H, Oguri T, Sato S, Maeda H, Niimi T, Ueda R : Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer. Cancer Sci 2004 ; 95 : 753-7.
12. Inoue A, Nukiwa T : Gene mutations in lung cancer: promising predictive factors for the success of molecular therapy. PLoS Med 2005 ; 2 : 20-2.
13. Di Maio M, Gridelli C, Normanno N, Perrone F, Ciardiello F : Trying to compose the puzzle with all the pieces: Epidermal growth factor receptor tyrosine-kinase inhibitors in non-small cell lung cancer. J Cell Physiol 2005 ; 205 : 355-63.
14. Clark J, Cools J, Gilliland G : EGFR inhibition in non-small cell lung cancer: resistance, once again, rears its ugly head. PLoS Med 2005 ; 2 : 195-7.
15. Han S-W, Hwang PG, Chung DH, Kim DW, Im SA, Kim YT, Kim TY, Heo DS, Bang YJ, Kim NK : Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa, ZD1839) in chemotherapy-resistant non-small cell lung cancer. Int J Cancer 2005 ; 113 : 109-15.
16. Kokubo Y, Gemma A, Noro R, Seike M, Kataoka K, Matsuda K, Okano T, Minegishi Y, Yoshimura A, Shibuya M, Kudoh S : Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA). Br J Cancer 2005 ; 92 : 1711-9.
17. Shepherd FA, Rodrigues-Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabarbara P, Seymour L : Erlotinib in previously treated non-small cell lung cancer. N Engl J Med 2005 ; 353 : 123-32.
18. Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J, Lorimer I, Zhang T, Liu N, Daneshmand M, Marrano P, Da Cunha-Santos G, Lagarde A, Richardson F, Seymour L, Whitehead M, Ding K, Pater J, Shepherd FA : Erlotinib in lung cancer - Molecular and clinical predictors of outcome. N Engl J Med 2005 ; 353 : 133-44.
19. Cappuzzo F, Hirsch F, Rossi E, Bartolini S, Ceresoli GL, Bemis L, Haney J, Witta S, Danenberg K, Domenichini I, Ludovini V, Magrini E, Gregorc V, Doglioni C, Sidoni A, Tonato M, Franklin WA, Crino L, Bunn PA Jr, Varella-Garcia M : Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small cell lung cancer. J Natl Cancer Inst 2005 ; 97 : 643-55.
20. Taron M, Ichinose Y, Rosell R, Mok T, Massuti B, Zamora L, Mate JL, Manegold C, Ono M, Queralt C, Jahan, Sanchez JJ, Sanchez-Ronco M, Hsue V, Jablons D, Sanchez JM, Moran T : Activating mutations in the tyrosine-kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. Clin Cancer Res 2005 ; 11 : 5878-85.
21. Cortes-Funes H, Gomez C, Rosell R, Valero P, Garcia-Giron C, Velasco A, Izquierdo A, Diz P, Camps C, Castellanos D, Alberola V, Cardenal F, Gonzalez-Larriba JL, Vieitez JM, Maeztu I, Sanchez JJ, Queralt C, Mayo C, Mendez P, Moran T, Taron M : Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small cell lung cancer patients. Ann Oncol 2005 ; 16 : 1081-6.
22. Han S-W, Kim TY, Hwang PG, Jeong S, Kim J, Choi IS, Oh DY, Kim JH, Kim DW, Chung DH, Im SA, Kim YT, Lee JS, Heo DS, Bang YJ, Kim NK : Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small cell lung cancer patients treated with gefitinib. J Clin Oncol 2005 ; 23 : 2493-500.
23. Mitsudomi T, Kosaka T, Endoh H, Horio Y, Hida T, Mori S, Hatooka S, Shinoda M, Takahashi T, Yatabe Y : Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small cell lung cancer with postoperative recurrence. J Clin Oncol 2005 ; 23 : 2513-20.
24. Tokumo M, Toyooka S, Kiura K, Shigematsu H, Tomii K, Aoe M, Ichimura K, Tsuda T, Yano M, Tsukuda K, Tabata M, Ueoka H, Tanimoto M, Data H, Gazdar AF, Shimizu N : The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancer. Clin Cancer Res 2005 ; 11 : 1167-73.
25. Sasaki H, Endo K, Konishi A, Takada M, Kawahara M, Iuchi K, Matsumura A, Okumura M, Tanaka H, Kawaguchi T, Shimizu T, Takeuchi H, Yano M, Fukai I, Fujii Y : EGFR mutation status in Japanese lung cancer patients: genotyping analysis using LightCycler. Clin Cancer Res 2005 ; 11 : 2924-9.
26. Chou T-Y, Chiu CH, Li LH, Hsiao CY, Tzen CY, Chang KT, Chen YM, Perng RP, Tsai SF, Tsai CM : Mutation in the tyrosine-kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer. Clin Cancer Res 2005 ; 11 : 3750-7.
27. Yang SH, Mechanic LE, Yang P, Landi MT, Bowman ED, Wampfler J, Meerzaman D, Hong KM, Mann F, Dracheva T, Fukuoka J, Travis W, Caporaso NE, Harris CC, Jen J : Mutations in the tyrosine-kinase domain of the epidermal growth factor receptor in non-small cell lung cancer. Clin Cancer Res 2005 ; 11 : 2106-10.
28. Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, Herbst RS, Ince WL, Janne PA, Januario T, Johnson DH, Klein P, Miller VA, Ostland MA, Ramies DA, Sebisanovic D, Stinson JA, Zhang YR, Seshagiri S, Hillan KJ : Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005, in press.
29. Weber F, Fukino K, Sawada T, Williams N, Sweet K, Brena RM, Plass C, Caldes T, Mutter GL, Villalona-Calero MA, Eng C : Variability in organ-specific EGFR mutational spectra in tumour epithelium and stroma may be the biological basis for differential responses to tyrosine-kinase inhibitors. Br J Cancer 2005 ; 92 : 1922-6.
30. Stephens P, Hunter C, Bignell G, Edkins S, Davies H, Teague J, Stevens C, O'Meara S, Smith R, Parker A, Barthorpe A, Blow M, Brackenbury L, Butler A, Clarke O, Cole J, Dicks E, Drozd A, Edwards K, Forbes S, Foster R, Gray K, Greenman C, Halliday K, Hills K, Kosmidou V, Lugg R, Menzies A, Perry J, Petty R, Raine K, Ratford L, Shepherd R, Small A, Stephens Y, Tofts C, Varian J, West S, Widaa S, Yates A, Brasseur F, Cooper CS, Flanagan AM, Knowles M, Leung SY, Louis DN, Looijenga LH, Malkowicz B, Pierotti MA, The B, Chenevix-Trench G, Weber BL, Yuen ST, Harris G, Goldstraw P, Nicholson AG, Futreal PA, Wooster R, Stratton MR : Intragenic ERBB2 kinase mutations in tumours. Nature 2004 ; 431 : 525-6.
31. Shigematsu H, Takahashi T, Nomura M, Majmudar K, Suzuki M, Lee H, Wistuba II, Fong KM, Toyooka S, Shimizu N, Fujisawa T, Minna JD, Gazdar AF : Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res 2005 ; 65 : 1642-6.
32. Lee JW, Soung YH, Kim SY, Park WS, Nam SW, Kim SH, Lee JY, Yoo NJ, Lee SH : Absence of the ERBB2 kinase domain mutation in lung adenocarcinomas in Korean patients. Int J Cancer 2005 ; 116 : 652-3.
33. Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, Singer S, Griffith DJ, Haley A, Town A, Demetri GD, Fletcher CDM, Fletcher JS : PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003 ; 299 : 708-10.
34. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, Velculescu VE : High frequency of mutations of the PIK3CA gene in human cancers. Science 2004 ; 304 : 554.
35. Stabile LP, Lyker J, Gubish CT, Zhang W, Grandis JR, Siegfried JM : Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects. Cancer Res 2005 ; 65 : 1459-70.
36. Ishibashi H, Suzuki T, Suzuki S, Niikawa H, Lu L, Miki Y, Moriya T, Hayashi S, Handa M, Kondo T, Sasano H : Progesterone receptor in non-small cell lung cancer - A potent prognostic factor and possible target for endocrine therapy. Cancer Res 2005 ; 65 : 6450-8.